-- Innovative single-device solution integrates proven FemVue and FemChec® technologies to support fallopian tube evaluation and improve workflow efficiency-- ATLANTA, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today it has received 510(k) clearance from the United States Food and Drug Administration... Read more
First and only delivery system designed specifically for premature infants with a patent ductus arteriosus (PDA), a life-threatening opening in their heart
New delivery system enables precise placement of Abbott's Amplatzer Piccolo Occluder in the tiniest babies
A PDA requiring treatment is present in approximately 20% of premature infants1 ABBOTT PARK, Ill., Dec. 18, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has received U.S. Food and Drug Administration... Read more
SAN DIEGO / Dec 18, 2025 / Business Wire / Tandem Diabetes Care, Inc. (Nasdaq: TNDM) a leading insulin delivery and diabetes technology company, today announced availability of the Tandem t:slim mobile application for Android and iOS users in Canada. The Tandem t:slim mobile app allows users to deliver a bolus from their compatible smartphone, and to wirelessly upload their pump data to the cloud-based Tandem Source platform.1
“With this release, we are furthering our... Read more
Collaboration expands Owlet’s national DME footprint, strengthens access for Medicaid and TRICARE families, and supports continued growth in prescription-backed revenue channel. LEHI, Utah / Dec 18, 2025 / Business Wire / Owlet, Inc. (“Owlet” or the “Company”) (NYSE: OWLT), the pioneer of smart infant monitoring, today announced a new durable medical equipment (DME) partnership with 1 Natural Way, a leading national mom-and-baby-focused DME provider. Families... Read more
Companies to leverage and collaborate on research and development, distribution, and regulatory expertise to accelerate global adoption of intelligent testing technologies
Alliance positions INBS to enter the fast-growing consumer health market, broadening revenue opportunities beyond commercial screening NEW YORK, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering... Read more
New 5-Year Agreement Provides Continued Financial Strength & Flexibility PONTE VEDRA, Fla., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced it has entered into a new five year $175 million senior secured loan arrangement with credit funds managed by SLR... Read more
THE WOODLANDS, TX, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced its abstract has been accepted for poster presentation at the 2026 ASCO Gastrointestinal Cancers Symposium, being held January 8-10, 2026 in San Francisco, CA.
Details of the poster presentation are as follows:
Title: Pain mitigation... Read more
NEW YORK & BURLINGTON, Mass. / Dec 18, 2025 / Business Wire / Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”), a digital health company transforming care with handheld, whole-body ultrasound and intuitive software, today announced that it will participate in the 44th Annual J.P. Morgan Healthcare Conference taking place January 12-15, 2026 in San Francisco, California.
Joseph DeVivo, President, Chief Executive Officer & Chairman; John Doherty, Executive Vice... Read more
Enrollment momentum accelerates as Company advances toward full enrollment White Bear Lake, Minnesota--(Newsfile Corp. - December 18, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that its pivotal clinical study for the investigational fully implanted Acclaim® cochlear implant has achieved yet another milestone by reaching the midway point of the... Read more
JAMA Oncology study highlights that Signatera-positive patients treated with celecoxib and conventional chemotherapy experienced a >40% reduction in risk of death, whereas Signatera-negative patients derived no significant benefit AUSTIN, Texas / Dec 18, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of findings from the randomized, phase III CALGB (Alliance)/SWOG 80702 study... Read more
SOUTH SAN FRANCISCO, Calif. / Dec 18, 2025 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the J.P. Morgan 2026 Healthcare Conference on Monday, January 12, 2026 at 2:15 pm Pacific Time in San Francisco.
The presentation will be webcast live and can be accessed by visiting the “Investor Calendar” page of the... Read more
WALTHAM, Mass. / Dec 18, 2025 / Business Wire / Revvity, Inc. (NYSE: RVTY) will present at the 44th annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 9:45 a.m. PT.
President and Chief Executive Officer Prahlad Singh will provide an update on the Company and its strategic priorities.
To access the presentation, a live audio webcast will be available on the Events section of the Company’s website. A replay of the presentation will be posted on the... Read more
WALTHAM, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the J.P. Morgan 2026 Healthcare Conference, being held January 12 – 15 in San Francisco. Olivier Loeillot, President and Chief Executive Officer, will present an overview of the company on Tuesday, January 13 at 2:15 p.m. PT.
A live webcast of the conference presentations... Read more
Includes Asthma in its strategic plans and Strengthens its Team in 2024-2025 Toronto, Ontario--(Newsfile Corp. - December 18, 2025) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, is pleased to provide an update on Investee company, InStatin.
InStatin, a biotechnology company developing inhaled statin therapies for respiratory... Read more
IRVINE, Calif. / Dec 18, 2025 / Business Wire / Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the J.P. Morgan Healthcare Conference on Monday, Jan. 12, 2026.
Bernard Zovighian, chief executive officer, is scheduled to present at 11:15 a.m. PT. Scott Ullem, chief financial officer, will also participate in the conference. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at htt... Read more
SEATTLE, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that Thijs Spoor, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Wednesday, January 14, 2026, at 2:15 p.m. PT.
44th Annual J.P. Morgan Healthcare... Read more
HAYWARD, Calif. / Dec 18, 2025 / Business Wire / Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for the Company’s Investigational Device Exemption (IDE), allowing Pulse Biosciences to proceed with the initiation of its nPulse Cardiac Catheter Ablation... Read more
BD FACSDiscover™ A8 Cell Analyzer to Enable Investigation of 30+ Cellular Characteristics to Capture Key Biological Insights and Support Planned 1,000-Person Immune Profiling Study FRANKLIN LAKES, N.J., Dec. 18, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a strategic collaboration with the Institute for Immunology and Immune Health (I3H) at the University of Pennsylvania, to advance... Read more
SALT LAKE CITY, Dec. 17, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has performed an in silico analysis of the Co-Primers® used in its Logix Smart® ABC test* for the detection of influenza A, influenza B and COVID-19. The analysis showed a high homology against 3,900 influenza sequences, confirming... Read more
Signing of definitive purchase agreement represents critical next step in completing previously announced acquisition SARASOTA, Fla. and INDIANAPOLIS, Dec. 17, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO” or the “Company”), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced that it has signed a definitive purchase agreement... Read more
India's Central Drugs Standard Control Organization (CDSCO) has approved the Hyperfine Swoop system, opening a major global market. Commercial launch to begin early 2026. GUILFORD, Conn. / Dec 17, 2025 / Business Wire / Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced the Swoop® system has received... Read more
Submission supported by positive preliminary 18-month NAUTILUS data in patients with drug-resistant idiopathic generalized epilepsy (IGE) and generalized tonic-clonic (GTC) seizures MOUNTAIN VIEW, Calif. / Dec 17, 2025 / Business Wire / NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that it has filed a Premarket Approval Supplement (PMA-S) application to the U.S. Food and... Read more
Distribution agreement with Singapore-based Verita Neuro will provide patients the ReWalk Personal Exoskeleton as part of its multi-layered treatment modalities
New delivery model for ReWalk will integrate in-patient training and rehabilitation to support clinical adoption in physical rehabilitation settings
Over 7 million survivors of spinal cord injury (SCI) globally could potentially benefit from ReWalk, an estimated $1.75 billion total addressable market for Lifeward... Read more
Distribution network coverage expanded to a total of 39 countries GARDEN CITY, N.Y., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced the recent signing of several key international distribution agreements for LungFit® PH, expanding its network... Read more
FRIENDSWOOD, Texas, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data from the largest prospective, multicenter study to date comparing next-generation sequencing (NGS)-based gene mutation analysis with the combination of DecisionDx-UM and Preferentially Expressed Antigen in Melanoma (PRAME) gene expression for predicting outcomes in patients with... Read more
VAUGHAN, Ontario / Dec 17, 2025 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Eduardo C. Alfonso, MD, and Steven H. Collis have been appointed to its board of directors. The appointments are effective Jan. 1, 2026, and following changes announced in August 2025 the board will be comprised of 10 directors.
“Eddie is one of the most prominent and... Read more
First Genio implants successfully performed at OLVG West and Zuyderland hospitals Mont-Saint-Guibert, Belgium – December 17, 2025, 7:05am CET / 1:05am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced the commercial launch of its Genio® system in the Netherlands, marked by the... Read more
Vivos Eyes High Growth Potential from Commercial Affiliation with Prominent Auburn Hills, Michigan Sleep Practice MISleep Solutions LITTLETON, Colo., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on sleep related breathing disorders, including obstructive sleep apnea (OSA), is pleased to announce the grand opening of its latest sleep testing... Read more
SANTA CLARA, Calif. / Dec 16, 2025 / Business Wire / Agilent Technologies Inc. (NYSE: A) today announced that CEO Padraig McDonnell and CFO Adam Elinoff will present at the 44th Annual J.P. Morgan Healthcare Conference at 9 to 9:40 a.m. PST on Tuesday, Jan. 13, 2026.
A live audio webcast and replay of the presentation will be available through Agilent’s Investor Relations website.
About Agilent Technologies
Agilent Technologies, Inc. (NYSE: A) is a global leader in analytical... Read more
Retrospective analysis at top-tier medical facility highlights AI solution’s ability to help spot previously missed cancers and correctly localize suspicious areas on mammograms MARLBOROUGH, Mass. / Dec 16, 2025 / Business Wire / Hologic, Inc. (Nasdaq: HOLX), a leading medical technology company dedicated to improving women’s health, today announced new data that highlights how the company’s advanced AI-powered mammography solution can aid in detecting more breast... Read more
Patent strengthens Company's global intellectual property portfolio and reinforces the Company's commitment to establishing and protecting competitive advantages White Bear Lake, Minnesota--(Newsfile Corp. - December 16, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced the issuance of Australian Patent No. 2022229818, granted by the Australian Patent... Read more
Latest findings from multicenter trial demonstrate Signatera’s ability to improve risk stratification for patients with therapy-resistant disease AUSTIN, Texas / Dec 16, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, together with Quantum Leap Healthcare Collaborative, today announced the publication of new findings from the I-SPY 2 trial in Nature Communications.
The study examined how Signatera can refine... Read more
New AI Models-as-a-Service offering to integrate in-silico design with experimental data to continuously improve predictive power and accelerate scientific innovation WALTHAM, Mass. / Dec 16, 2025 / Business Wire / Revvity, Inc. (NYSE: RVTY) today announced the introduction of its forthcoming Signals Xynthetica™ Models-as-a Service (MaaS) AI offering within the Revvity Signals platform. The Signals Xynthetica offering will enable AI-augmented molecular and materials... Read more
OneStep's Clinically Validated Mobility Intelligence Technology to Integrate into Zimmer Biomet's mymobility® Care Management Platform to Further Enhance Recovery Monitoring WARSAW, Ind., Dec. 16, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, and OneStep, the FDA-listed digital fall prevention and mobility intelligence platform, today announced an exclusive collaboration agreement aimed at delivering... Read more
WALTHAM, Mass., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the launch of three new high-performance chromatography resins: AVIPure® HiPer™ AAV9 and AVIPure® HiPer™ AAV8 affinity resins, along with HiPer™ QA anion exchange resin, expanding the company’s growing proteins portfolio and reinforcing its commitment to innovation in next-generation... Read more
FRANKLIN LAKES, N.J., Dec. 15, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the expansion of its respiratory and sexually transmitted infection (STI) diagnostics offerings in Europe following In Vitro Diagnostic Medical Device Regulation (IVDR) certification of two VIASURE assays developed by Certest Biotec for use on the BD MAX™ System. The addition of these new assays to the BD MAX™... Read more
MENLO PARK, Calif., Dec. 15, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, Jan. 12 at 7:30 a.m. PT.
Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at investors.grail.com. The webcast will be archived... Read more
Company advances its mission to deliver next-generation diabetes management solutions and expand global market penetration
Next-generation column technology enhances efficiency, expands recurring revenue potential, and strengthens Trinity Biotech’s competitive position in the $2B+ HbA1c market DUBLIN, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management... Read more
Southlake, TX, Dec. 15, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company advancing the use of ECG/EKGs through the integration of artificial intelligence (“AI”), today announced it has submitted its MyoVista® wavECG™ device to the U.S. Food and Drug Administration (“FDA”) for 510(k) premarket clearance.
The MyoVista wavECG device is designed... Read more
A new multi-direction DWI sequence, the latest Swoop® system software, and the first advancement in Hyperfine’s Optive AI™ software, delivers clearer, higher-quality images for stroke diagnosis, enhancing the value of the Swoop® system in acute neurological care. GUILFORD, Conn. / Dec 15, 2025 / Business Wire / Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable... Read more
Quipt shareholders to receive US$3.65 per share in cash
Transaction provides immediate liquidity and certainty of value to shareholders
The per share purchase price represents a 162% premium to Quipt’s unaffected stock price on May 19, 2025, the last full trading day prior to the public disclosure of Forager’s $3.10 per share proposal, and a 54% premium to Quipt’s 30-day VWAP as of December 12, 2025 CINCINNATI, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Quipt Home Medical... Read more
CINCINNATI, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the “Company”) (NASDAQ: QIPT; TSX:QIPT), a U.S.-based home medical equipment provider focused on end-to-end respiratory care, today announced its fourth quarter and fiscal year 2025 financial results and operational highlights. These results pertain to the three months and year ended September 30, 2025 and are reported in U.S. Dollars under GAAP.
Financial Highlights: Revenue for Q4 2025 was... Read more
RA'ANANA, Israel, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN, IINNW) ("Inspira," “Inspira Technologies,” or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that it has entered into a definitive agreement with YA II PN, Ltd. (“YA”) for a registered direct offering of its ordinary shares, and has also entered into a Standby Equity Purchase Agreement (“SEPA”)... Read more
Southlake, TX, Dec. 15, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), today reported financial results for its fiscal second quarter ended October 31, 2025 (“FQ2 2026”) and provided a business update.
Second Quarter and Recent... Read more
Multicenter, Signatera™ Genome-guided interventional trial will evaluate different treatment approaches in HR+/HER2- breast cancer AUSTIN, Texas / Dec 12, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, and MEDSIR (Medica Scientia Innovation Research), a global leader in oncology research, today announced their collaboration on the MiRaDoR (NCT05708235) study, which is a multicenter, phase II clinical trial... Read more
Across multiple published studies, the test consistently identifies high-risk patients whose progression rates exceed guideline-based actionable thresholds for intensified care FRIENDSWOOD, Texas, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a new systematic review and meta-analysis (SRMA) demonstrating that the TissueCypher® Barrett’s... Read more
Toronto, Ontario--(Newsfile Corp. - December 12, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses, has commenced a non-brokered private placement of units of the Company ("Units") to raise up to $CAN 2,000,000 ("Offering").
In the Offering, each Unit is priced... Read more
New data reveals Oncodetect’s powerful prognostic performance in one of the largest TNBC MRD studies to date1 MADISON, Wis. / Dec 11, 2025 / Business Wire / Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the first clinical study results from its Oncodetect® molecular residual disease (MRD) test in breast cancer. Findings from the NSABP B-59 substudy, conducted in collaboration with the NSABP Foundation... Read more
Toronto, Ontario--(Newsfile Corp. - December 11, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a leader in the development of diagnostic and prognostic tests for human disease through the analysis of telomeres, today announced that the company highlighted its approach to Multiple Myeloma (MM) Minimal Residual Disease (MRD) testing with a poster presentation during the 67th American Society of Hematology (ASH) Annual Meeting in Orlando,... Read more
KIRKLAND, Wash., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today reported financial results for the second quarter fiscal 2026, which ended October 31, 2025.
Financial Highlights Generated revenue of $22.6 million in Q2 FY26, an increase of 53% compared to the prior year period.
Expanded gross margin to 50.6% in Q2 FY26 compared to 39.6% in the prior year period.
Increased... Read more
